Drugs / VX-272
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07437105 | Feb 2026 → Mar 2027 expected | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-272 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07437105 ↗ |
| Route | Oral | “Suspension for Oral Administration.” NCT07437105 ↗ |